ArticleThe oncologist2011

Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?

Simona Soverini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.